LABORATOIRES-DELBERT
25.4.2022 09:32:12 CEST | Business Wire | Press release
Today, Laboratoires DELBERT is proud to announce the signature with Sanofi on March 31st, 2022 of the acquisition of Teralithe 250mg, divisible tablet and Teralithe LP 400mg, prolonged-release tablet (lithium carbonate) in France.
Laboratoires DELBERT (https://laboratoires-delbert.fr/ ) is a French Pharmaceutical company specialized in the « Revival of essential medications » : Marketing discontinuation, stock shortages …affect more and more essential medications especially in crisis periods with the consequence of narrowing the therapeutic arsenal of doctors that may force well-controlled patients to switch to other therapies.
With this acquisition Laboratoires DELBERT reinforces the execution of their strategy in order to ensure safe and continuous availability of Essential Medications to patients and reinforce their CNS portfolio.
“This acquisition demonstrates our ongoing commitment to invest in Major Therapeutical Interest Medications (MITM). Maintaining these medications available for patients in need is our priority,” said Marc Childs, & Thierry Hoffmann co-founders of Laboratoires DELBERT, « Laboratoires DELBERT built up over the time a portfolio of MITM that is anchored in 3 specific therapeutic areas : Antiinfectives, CNS and Oncology. »
Laboratoires DELBERT will reach over 30m€ sales by 2022 with double digit growth every year and already commercializes 14 products (out of which 13 princeps) for hospitals/specialists prescriptions.
Laboratoires DELBERT financed this acquisition thanks to very strong relationship with its financial partners who strongly believe in their values focused on patients access to MITM.
About Laboratoires DELBERT
Laboratoires DELBERT’ mission is to maintain Major Therapeutical Intererest Medication (MITM) and frequently used, available for patients.
Every year Laboratoires Delbert acquires new specialities with compromised future.
Laboratoires DELBERT focus their efforts on finding production facilities mainly across Europe.
With its collaborators and support from clinicians, galenicians, chemists Laboratoires DELBERT revive those medications and ensure their availability for clinicians and their patients in needs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220424005065/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carta Launches Unified Fund of Funds Solution to Automate LP Workflows and Portfolio Visibility24.3.2026 11:01:00 CET | Press release
New AI-powered offering closes the gap between investment data and investor reporting, bringing institutional-grade automation to complex Fund of Funds structures Carta, the world’s first fully interconnected system for private capital, today announced its solution for Fund of Funds, a new offering designed to help managers automate LP reporting, eliminate manual document processing, and gain clearer visibility into their underlying portfolio exposure. The product expands a critical link in Carta’s ERP for private capital, bringing LP investment data, fund accounting, and portfolio analytics onto a single platform, while more deeply connecting allocators with the GP ecosystem. Fund of Funds represents a critical and growing segment of the private capital ecosystem, projected to reach $450 billion by 2033 as investors seek diversified exposure to private markets. Yet, operating a fund of funds remains highly complex. Managers sit at a unique intersection of the ecosystem, investing as L
Meeting Rising AI Expectations and Removing Friction Key to Meeting Needs of B2B Buyers Across Europe24.3.2026 11:00:00 CET | Press release
8 in 10 buyers use AI in payments, but strategic integration remains uneven and caution abounds in France and GermanyPay by invoice, a core European expectation, a major growth lever in 2026, but payment preferences vary by country and company size According to a new European study1 of 550 business buyers commissioned by TreviPay, the global B2B payments invoicing and payments network, friction in the B2B buying process in the form of slow onboarding and inconsistent invoicing along with rising expectations for AI-enabled processes are where businesses are experiencing threats to loyalty beyond price. “Across Europe and the UK, finance teams are navigating economic pressure, regulatory complexity and rising buyer expectations,” said Inez Berkhof-Hollander, TreviPay’s Vice President of EMEA. “Our research shows payment and invoicing experiences now play a decisive role in supplier selection.” Top Three European Market Expectations in 2026 1. More AI-driven purchasing options vary by cou
OCTO and Volkswagen Group Info Services AG Form Partnership for Fleet Data Integration24.3.2026 10:00:00 CET | Press release
The partnership enables secure integration of vehicle data from six Volkswagen Group brands into OCTO’s platform, strengthening fleet data services across the European Union and supporting utilization, maintenance and geo-location use cases without additional hardware. OCTO, a leading company in the field of telematics, data analytics and AI-driven solutions for insurance and fleet management, announces a strategic partnership with Volkswagen Group Info Services AG. The goal of this cooperation is to expand data solutions for fleet operators by directly integrating vehicle data from the brands Volkswagen Passenger Cars, Volkswagen Commercial Vehicles, Škoda, Seat, Cupra and Audi. Through this partnership, OCTO gains direct access to vehicle data from fleet vehicles of these six Volkswagen brands. This enables innovative mobility services for fleet managers, including maintenance management, theft protection, damage management, fraud detection, driving behavior analysis, activity report
Wolters Kluwer-undersøgelse: Danske SMV'er er førende i Europa inden for AI-drevet omkostningsbesparelser24.3.2026 10:00:00 CET | Pressemeddelelse
Høj reguleringsparathed og pragmatisk teknologiimplementering hjælper virksomheder med at skabe afkast, selvom finansieringsbegrænsningerne vokser Wolters Kluwer Tax & Accounting har i dag offentliggjort sin første rapport Future Ready Businessder viser, at danske små og mellemstore virksomheder (SMV'er) er de mest tilfredse i Europa med AI-drevet omkostningsbesparelser. Blandt SMV'er, der bruger AI, siger 65 %, at det har overgået forventningerne til omkostningsreduktion, hvilket er det stærkeste resultat på tværs af alle EU-markeder, langt foran lande som Tyskland og Spanien. Undersøgelsens resultater tegner et kontrastfyldt billede af markedet, hvor danske SMV'er kombinerer høj reguleringsparathed og en stærk præference for strategisk outsourcing med et stigende pres fra stigende omkostninger og begrænset adgang til kredit. "AI i Danmark implementeres med et klart forretningsmæssigt formål, ikke som en teknologisk trend," siger Martin Tage, Country Manager, Wolters Kluwer Tax & Acco
Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 202624.3.2026 09:30:00 CET | Press release
First preclinical data on the Company’s lead program MOS101: a combination of ASTX295, a next-generation, clinical-stage MDM2 antagonist, and olaparib, an FDA-approved PARP inhibitor, in biomarker-selected solid tumorsAdditional data showcasing Mosaic’s Discovery Platform, PRIME, will be presented Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA. Poster Presentation Details: Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors” Abstract Number: 3053 Date and Time: Monday, April 20, 2026, 2:00PM – 5:00PM PST Session Category: Novel Targets and Pathways Session: PO.ET09.09 Location: Poster Section 15 For more information an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom